Bayer's Nexavar hits endpont in thyroid cancer trial; AbbVie plans hiring in Ireland;

@FiercePharma: Dr Reddy's launches Propecia generic with 180-day exclusivity; worth $20M to Indian company, analysts say. Story | Follow @FiercePharma

> Bayer said its cancer treatment Nexavar hit a goal of improving the survival of patients with a certain type of thyroid cancer in a late-stage clinical trial. Report

> AbbVie ($ABBV), the newly independent pharma business of Abbott Laboratories ($ABT), will add 175 jobs in Ireland by 2015, the company said. Report

> Forest Laboratories ($FRX) settled its Bystolic patent litigation with Glenmark Pharma, allowing the Indian company to sell its generics three months before the patent expires. Report

> Denmark's pharma market is expected to grow by an average of 6.9% a year to reach $7.3 billion by 2020, up from $4 billion in 2011, says a new report, from GlobalData. Report

> Ulcerative colitis patients will drive drug sales to $3.7 billion over the next decade, double their current level, with AbbVie's Humira and Johnson & Johnson's ($JNJ) Simponi benefiting most, a report says. Report

Medical Device News

 @FierceMedDev: Cardiologist: Boston Scientific's S-ICD requires further trials. More | Follow @FierceMedDev

@MarkHFierce: A German company is rolling out a new diagnostic test for the early prediction of breast cancer. Release | Follow @MarkHFierce

 @DamianFierce: Smith & Nephew's quasi-spinout, Bioventus, is expanding its European reach. Story | Follow @DamianFierce

> Crescendo Bioscience draws $28M Series D for RA Dx. News

> FDA: Praxair's recalled oxygen tanks pose deadly fire risk. Item

Biotech News

 @FierceBiotech: Sanofi Pasteur, Sutro team up on #vaccine candidates. Item | Follow @FierceBiotech

@JohnCFierce: In biotech trifecta, startup lassos $31M, a CEO and a lead drug from Pfizer. More  | Follow @JohnCFierce

@RyanMFierce: Repligen took in $5M of potential $70M from Pfizer in deal for candidate against spinal muscular dystrophy. More | Follow @RyanMFierce

> Wellcome Trust gambles on biotech startups with new £200M fund. Story

> Biogen CEO Scangos hit with first big setback as ALS drug fails PhIII. News

Vaccines News

 @AlisonBFierce: Sanofi Pasteur MSD's recall of its typhoid vaccine has led to a shortage in the U.K. More | Follow @AlisonBFierce

> Sanofi Pasteur, Sutro team up on vaccine candidates. Item

> HIV therapeutic vaccine shows promise. More

> Emergent, VaxInnate sign pandemic flu vaccine deal. Article

Pharma Manufacturing News

> Questcor buys CMO that makes API for Acthar. More

> BASF gets Vascepa contract ahead of Pronova buyout. News

> Pakistan investigates cough syrup tied to 35 deaths. Item

> Russia pushes plan to buy domestically produced drugs. Story

> FDA warns docs to buy from approved suppliers. Article

And Finally... Should diet and depression be studied the same way diet has been tested in heart disease? Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.